Investor Presentaiton

Reimbursement pathway for Shield starts with colorectal cancer indication INVESTOR 20 DAY 23 >shield™ CRC Clear pathway starting with CRC Medicare Coverage Blood-based CRC screening NCD with 3-year interval Private Coverage ACS and USPSTF guidelines Access ~120M individuals National Coverage Determination (NCD) Colorectal Cancer Screening Tests 210.3 Expand All | Collapse All Effective for dates of service on or after January 19, 2021, a blood-based biomarker test is covered as an appropriate colorectal cancer screening test once every 3 years for Medicare beneficiaries when performed in a Clinical Laboratory Improvement Act (CLIA)-certified laboratory, when ordered by a treating physician and when all of the following requirements are met: The patient is: ⚫ age 50-85 years, and, asymptomatic (no signs or symptoms of colorectal disease including but not limited to lower gastrointestinal pain, blood in stool, positive guaiac fecal occult blood test or fecal immunochemical test), and, at average risk of developing colorectal cancer (no personal history of adenomatous polyps, colorectal cancer, or inflammatory bowel disease, including Crohn's Disease and ulcerative colitis; no family history of colorectal cancers or adenomatous polyps, familial adenomatous polyposis, or hereditary nonpolyposis colorectal cancer). The blood-based biomarker screening test must have all of the following: • Food and Drug Administration (FDA) market authorization with an indication for colorectal cancer screening; and, ⚫proven test performance characteristics for a blood-based screening test with both sensitivity greater than or equal to 74% and specificity greater than or equal to 90% in the detection of colorectal cancer compared to the recognized standard (accepted as colonoscopy at this time), as minimal threshold levels, based on the pivotal studies included in the FDA labeling National Coverage Determination by CMS GUARDANT™ 109

View entire presentation